Asset
GOLODIRSEN
Sarepta Therapeutics Inc. Common Stock (DE)
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03532542 | phase3 | terminated | 2018-08-02 | 2023-07-26 | Sarepta Therapeutics, Inc. | An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy |
| NCT02310906 | phase1_2 | completed | 2015-01-13 | 2019-03-25 | Sarepta Therapeutics, Inc. | Phase I/II Study of SRP-4053 in DMD Patients |
| NCT02500381 | phase3 | completed | 2016-09-28 | 2024-11-12 | Sarepta Therapeutics, Inc. | Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 211970 | NDA | SAREPTA THERAPEUTICS INC |
Marketed products (1)
- VYONDYS 53